| 发明名称 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | ||
| 摘要 | The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8. | ||
| 申请公布号 | US8759310(B2) | 申请公布日期 | 2014.06.24 |
| 申请号 | US201213353905 | 申请日期 | 2012.01.19 |
| 申请人 | Idera Pharmaceuticals, Inc. | 发明人 | Kandimalla Ekambar R.;Lan Tao;Li Yukui;Yu Dong;Wang Daqing;Putta Mallikarjuna Reddy;Agrawal Sudhir |
| 分类号 | A61K48/00;A61K49/00;A61K39/00;A61K45/00;A61K47/00;C07H21/04 | 主分类号 | A61K48/00 |
| 代理机构 | Wood, Philips, Katz, Clark & Mortimer | 代理人 | Wood, Philips, Katz, Clark & Mortimer |
| 主权项 | 1. A method for generating a TLR8-, TLR7 and TLR8-, or TLR7-mediated immune response in a vertebrate, the method comprising administering to the vertebrate a biologically stable, biologically active agonist for TLR8, TLR7 and TLR8, or TLR7, consisting essentially of two single-stranded oligoribonucleotides linked through a 3′-3′ attachment, wherein each of the oligoribonucleotides is 8 to 17 ribonucleotides in length, wherein the sequences of the oligoribonucleotides are identical, and wherein the agonist is not associated with a lipid, condensed with polyethylenimine, or complexed to DOTAP. | ||
| 地址 | Cambridge MA US | ||